ESPR: Esperion Therapeutics, Inc. Stock

by  •  • Comments Off on ESPR: Esperion Therapeutics, Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 364.52
Enterprise Value ($M) 482.72
Book Value ($M) -370.21
Book Value / Share -1.88
Price / Book -0.98
NCAV ($M) -376.77
NCAV / Share -1.91
Price / NCAV -0.97

Profitability (mra)
Return on Invested Capital (ROIC) n/a
Return on Assets (ROA) -0.42
Return on Equity (ROE) n/a

Liquidity (mrq)
Quick Ratio 1.37
Current Ratio 1.85

Balance Sheet (mrq) ($M)
Current Assets 307.56
Assets 314.11
Liabilities 684.32
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income 0.00
Net Income 0.00
Earnings Per Share Basic And Diluted n/a
Earnings Per Share Diluted n/a
Earnings Per Share Basic n/a

Cash Flow Statement (mra) ($M)
Cash From Operations 0.00
Cash from Investing 0.00
Cash from Financing 0.00

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
9 days ago 13G/A Bb Biotech Ag
11-14 13G/A Two Seas Capital LP 3.30 -14.34
11-12 13G/A Vanguard Group Inc 6.64 0.00
11-08 13G BlackRock, Inc. 7.30 0.00
10-17 13G/A Millennium Management Llc 1.70 -66.56
2024-02-14 13G/A CVI Investments, Inc. 0.00 -100.00
2024-02-14 13G/A Point72 Asset Management, L.P. 0.20 -95.37
2024-02-14 13G/A Deep Track Capital, LP 0.00 -100.00
2024-02-09 13G/A Wasatch Advisors Inc

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-11-07 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 ☐ TRANSITION REPORT PURSUANT
2024-08-12 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 ☐ TRANSITION REPORT PURSUANT TO S
2024-05-07 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT PURSUANT TO
2024-02-27 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT PURSUA

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2025-02-21 451,463 1,792,225 25.19
2025-02-20 479,550 1,461,022 32.82
2025-02-19 548,367 1,897,389 28.90
2025-02-18 349,686 1,423,085 24.57

(click for more detail)

Similar Companies
CURR – CURRENC Group Inc. CVAC – CureVac N.V.
EOLS – Evolus, Inc. ETNB – 89bio, Inc.
ETON – Eton Pharmaceuticals, Inc.


Financial data and stock pages provided by
Fintel.io